Telix Pharmaceuticals is spending up to $2.35 billion to acquire ITM Isotope Technologies, and the real story isn't the pipeline. It's a high-stakes bet on controlling the fragile supply chain that the entire radiopharmaceutical industry depends on.
In the radiopharmaceutical industry, the hottest commodity isn't a drug. It's the stuff you need to make the drug.
Telix Pharmaceuticals just agreed to buy ITM Isotope Technologies Munich SE for up to $2.35 billion. On the surface, that looks like a classic biotech acquisition: one company buying another for its pipeline. But look closer, and this deal is really about plumbing. Telix isn't just buying drugs. It's buying the raw materials, the reactors, and the production lines that the entire industry depends on.
And that tells you everything about where radiopharmaceuticals are headed.
The Deal, Decoded
The headline number is $2.35 billion, but the actual structure is more nuanced. Telix is paying $1.65 billion upfront, mostly in stock: roughly $1.25 billion in Telix shares (105.8 million shares), plus about $302 million of ITM's net debt that Telix will absorb, and $96 million for management equity rollover and transaction costs.
The remaining $700 million is contingent. Those payments kick in only if ITM's lead therapeutic candidate, ITM-11, hits specific regulatory approvals and sales milestones. Telix can pay those milestones in cash or stock, at its discretion.
After the dust settles, existing Telix shareholders will own about 76.3% of the combined company. ITM's shareholders get the remaining 23.7%. It still needs shareholder votes and regulatory clearances, but the intent is clear: Telix wants to become a vertically integrated radiopharmaceutical powerhouse.
Think of it like a restaurant chain buying a cattle ranch. You're not just adding menu items; you're securing the supply of beef.
The Isotope Problem Nobody Talks About
To understand why this deal matters, you need to understand a dirty little secret of the radiopharmaceutical boom: there aren't enough isotopes to go around.
Radiopharmaceuticals use radioactive isotopes to find and kill cancer cells. The two hottest isotopes right now are (Lu-177, used in treatments like Novartis's Pluvicto) and (Ac-225, an alpha-emitter generating enormous clinical interest). Both are incredibly difficult to produce at scale.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
lutetium-177
actinium-225
Lu-177 requires high-flux nuclear reactors and enriched ytterbium-176 as a starting material. The problem? Only a handful of reactors worldwide can do the job, and Russia has historically been the primary source of enriched Yb-176. One European study found that even if current production capacity roughly doubled over the next decade, it would only support about 3% annual growth in demand, which falls short of projected needs.
The real-world consequences are already here. In 2023, Novartis faced supply shortages for Pluvicto after demand outpaced production. And that's before you account for the dozens of new radiopharmaceutical programs entering the clinic.
For Ac-225, the bottleneck is even tighter. Production depends on a tiny number of facilities, and the infrastructure simply hasn't caught up with clinical ambition.
This is the context that makes Telix's acquisition click into place.
What ITM Actually Brings to the Table
ITM isn't some scrappy startup with a promising molecule. It's one of the world's largest producers of non-carrier-added Lu-177, supplying clinics, researchers, and pharma companies in more than 60 countries. Its flagship product, EndolucinBeta (a GMP-manufactured Lu-177 precursor), has EU marketing authorization and an active U.S. FDA Drug Master File.
The company operates a major production facility in Garching, near Munich, where it has significantly expanded capacity. It also locked down a deal with the Institute Laue-Langevin for priority access to half of the available neutron irradiation capacity at ILL's high-flux reactor. That's not a partnership; that's a strategic moat.
ITM also supplies Lu-177 to multiple development programs across the industry, including agreements with Y-mAbs, Radiopharm, and a long-term supply deal (through 2035) originally signed with Endocyte for Lu-177-PSMA-617, the molecule that became Pluvicto.
So when Telix writes a $2.35 billion check, it's buying manufacturing scale, reactor access, global distribution, and a customer base that reads like a who's who of radiopharmaceutical development. Plus a therapeutic pipeline anchored by ITM-11.
The Radiopharmaceutical Land Grab
Telix isn't operating in a vacuum. The last two years have been an absolute feeding frenzy in radiopharmaceuticals, and the biggest players in pharma are the ones writing the checks.
Bristol Myers Squibb grabbed RayzeBio for about $4.1 billion in early 2024, picking up an actinium-based platform. AstraZeneca spent roughly $2 billion on Fusion Pharmaceuticals to enter targeted alpha therapies. Novartis bought Mariana Oncology for $1 billion upfront (plus milestones) to strengthen its Ac-225 pipeline. Eli Lilly acquired POINT Biopharma for about $1.4 billion, then followed up with partnership deals with Aktis Oncology and Radionetics Oncology.
Notice the pattern? Every major pharma company with oncology ambitions is racing to lock up radiopharmaceutical assets. And increasingly, they're not just buying pipelines. GE HealthCare has been snapping up manufacturing and distribution infrastructure. Lantheus acquired Evergreen Theragnostics for its development and manufacturing capabilities.
The industry is consolidating around a simple thesis: if you don't control your isotope supply, you don't control your destiny.
Why This Could Be Telix's Smartest Move
Telix is already a profitable radiopharmaceutical company, which puts it in rare company. It generated about $804 million in revenue in 2025, driven by its imaging products Illuccix and Gozellix. First-half 2026 revenue came in at $477 million, suggesting the growth trajectory remains intact.
But Telix's ambitions go well beyond imaging. Its therapeutic pipeline includes TLX591-Tx in phase 3 for metastatic prostate cancer, TLX101-Tx for recurrent glioblastoma, and TLX250-Tx for kidney cancer. To run those programs (and eventually manufacture those therapies at scale), Telix needs a reliable, controlled source of isotopes.
Analysts have been broadly positive on the deal, with some describing it as a move into "Novartis territory" because it combines therapeutic development with supply-chain control. The risk, of course, is execution. Integrating a complex manufacturing operation across continents is hard. The $700 million in contingent payments depends on ITM-11 clearing regulatory hurdles and hitting commercial targets. And the share-based consideration means existing Telix holders are absorbing real dilution.
But the strategic logic is hard to argue with. In a world where isotope shortages can literally shut down your drug supply (just ask Novartis circa 2023), owning the factory isn't a luxury. It's a necessity.
The Bigger Picture
Radiopharmaceuticals are having their moment. They represent one of oncology's fastest-growing treatment categories, with the ability to deliver targeted radiation directly to tumor cells while sparing healthy tissue. The science is compelling. The clinical data is encouraging. The commercial opportunity is massive.
But none of it works without isotopes. And the global supply chain for those isotopes is fragile: dependent on aging reactors, concentrated in a few countries, and constrained by complex chemistry that can't be scaled up overnight.
Telix's bet on ITM is ultimately a bet that the companies who win in radiopharmaceuticals won't just be the ones with the best drugs. They'll be the ones who can actually make them.
Deals & M&A4 min read
Zymeworks Just Became a Completely Different Company
Zymeworks dropped $929 million to acquire Theravance Biopharma, and the deal transforms it from a clinical-stage antibody shop into a diversified cash-flow machine. The financing structure is unusually clever, and Wall Street is paying attention.
